Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

But the groups have yet to see any responses with AU-007 and XTX202 respectively.